Silo Pharma, Inc. financial data

Symbol
SILO on Nasdaq
Location
677 N. Washington Blvd, Sarasota, FL
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 549 % -27.8%
Debt-to-equity 38.9 % +32.9%
Return On Assets -77.1 % -59.4%
Operating Margin -7.36K % -30.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 13.3M shares +197%
Common Stock, Shares, Outstanding 10.5M shares +133%
Entity Public Float 3.43M USD -42.5%
Common Stock, Value, Issued 1.05K USD +133%
Weighted Average Number of Shares Outstanding, Basic 9.33M shares +117%
Weighted Average Number of Shares Outstanding, Diluted 9.33M shares +117%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 72.1K USD 0%
Cost of Revenue 25.1K USD +329%
Research and Development Expense 2.99M USD +91.3%
Operating Income (Loss) -5.31M USD -30.9%
Nonoperating Income (Expense) 231K USD -32.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -5.08M USD -36.7%
Income Tax Expense (Benefit) 906K USD +50.3%
Net Income (Loss) Attributable to Parent -5.08M USD -34.2%
Earnings Per Share, Basic 0 USD/shares +22.7%
Earnings Per Share, Diluted 0 USD/shares +22.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.92M USD -19.4%
Assets, Current 6.16M USD -25.4%
Intangible Assets, Net (Excluding Goodwill) 220K USD -9.82%
Assets 6.38M USD -25.5%
Accounts Payable, Current 144K USD
Contract with Customer, Liability, Current 72.1K USD 0%
Liabilities, Current 708K USD -32.2%
Contract with Customer, Liability, Noncurrent 668K USD -9.75%
Liabilities 1.38M USD -22.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 11.3K USD -42.7%
Retained Earnings (Accumulated Deficit) -18.6M USD -37.5%
Stockholders' Equity Attributable to Parent 5.01M USD -26.1%
Liabilities and Equity 6.38M USD -25.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.64M USD -95.7%
Net Cash Provided by (Used in) Financing Activities -115K USD
Net Cash Provided by (Used in) Investing Activities 871K USD +793%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 10.5M shares +133%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.92M USD -19.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 2.07K USD +10.5%
Deferred Tax Assets, Valuation Allowance 3.71M USD +46.2%
Deferred Tax Assets, Gross 3.71M USD +46.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -5.09M USD -35.1%
Lessee, Operating Lease, Liability, to be Paid 1.88M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 1.88M USD
Deferred Tax Assets, Operating Loss Carryforwards 2.96M USD +25.6%
Preferred Stock, Shares Authorized 5M shares 0%
Additional Paid in Capital 23.6M USD +16.3%
Amortization of Intangible Assets 3.09K USD
Deferred Tax Assets, Net of Valuation Allowance 2.54M USD +63.7%
Share-based Payment Arrangement, Expense 0 USD
Interest Expense 5.08K USD +13%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%